PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 30, 2025Blood AdvancesOpen Access

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMorgane CheminantRHRoch HouotEGElodie Gat

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cheminant et al. (2025) studied this question.

synapsesocial.com/papers/6a931178fbc2fa2140701b21https://doi.org/10.1182/bloodadvances.2025017234
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brexucabtagene autoleucel in‐vivo expansion and BTKi refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from CART ‐ SIE study2024 · 8 citations
  2. 2Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study2023 · 111 citations